Anaphylaxis Treatment Guidelines

Primary Treatment of Anaphylaxis

• The American Academy of Allergy, Asthma, and Immunology recommends epinephrine as the first-line therapy for anaphylaxis, which should never be delayed or replaced by antihistamines, with a dosage of 0.01 mg/kg of 1:1000 concentration, maximum 0.5 mg, administered into the vastus lateralis for optimal absorption 1, 2
• Delay in administering epinephrine is associated with anaphylaxis fatalities and increased risk of biphasic reactions, highlighting the importance of prompt treatment 1, 2

Evidence for H1 Antihistamines in Anaphylaxis

• H1 antihistamines address only cutaneous manifestations of anaphylaxis, such as itching, urticaria, and flushing, which are not life-threatening, with a slow onset of action and lack of vasoconstrictive, bronchodilatory, ionotropic, and mast cell stabilization properties 1, 2, 3
• The strength of evidence for H1 antihistamines in anaphylaxis is limited, with indirect evidence supporting their use, and key limitations include their slow onset of action, typically 30 minutes to start working and 60-120 minutes to reach peak plasma levels 2, 3

Evidence for H2 Antihistamines in Anaphylaxis

• A systematic review found no high-quality evidence supporting the use of H2 antihistamines in anaphylaxis, with H2 receptors primarily found in the gastrointestinal tract and limited distribution in vascular smooth muscle cells 1, 2, 3
• H2 antihistamines play a minor role in the pathophysiology of anaphylaxis, with their use not recommended as a primary treatment for anaphylaxis 3

Clinical Application of Antihistamines in Anaphylaxis Management

• If antihistamines are used, they should only be administered after epinephrine in patients with anaphylaxis, with first-generation H1 antihistamines such as diphenhydramine 25-50 mg commonly used for oral and IV dosing 1, 2, 4
• Some clinicians use H1 and H2 antihistamines concurrently, but rigorous studies supporting this approach in anaphylaxis are lacking, with one study showing improved resolution of urticaria when combining H1 and H2 antagonists in acute allergic syndromes 4

Common Pitfalls in Anaphylaxis Management

• Using antihistamines as first-line treatment instead of epinephrine is a dangerous practice that can lead to delayed treatment of life-threatening symptoms, with sedation from first-generation H1 antihistamines contributing to decreased awareness of anaphylaxis symptoms 1, 2, 4
• Relying on antihistamines alone to treat anaphylaxis is inadequate, as they cannot address cardiovascular collapse or respiratory distress, highlighting the importance of epinephrine as the primary treatment 1, 2

Anaphylaxis Treatment Guidelines

Primary Treatment

• The American Academy of Allergy, Asthma, and Immunology recommends epinephrine as the only first-line treatment for anaphylaxis, with no absolute contraindications, and must be administered immediately at 0.01 mg/kg of 1:1000 concentration (maximum 0.5 mg in adults, 0.3 mg in children) intramuscularly into the vastus lateralis 5, 6, 7, 8
• Delay in administering epinephrine is directly associated with anaphylaxis fatalities and increased risk of biphasic reactions, as stated by the American College of Radiology 5, 7

Glucocorticoids in Anaphylaxis Treatment

• Glucocorticoids have a slow onset of action (4-6 hours minimum) because they work by binding to glucocorticoid receptors, translocating to the nucleus, and inhibiting gene expression—a process that cannot reverse acute anaphylactic symptoms, according to the Journal of Allergy and Clinical Immunology 8
• The American Academy of Otolaryngology-Head and Neck Surgery states that glucocorticoids are not reliable interventions to prevent biphasic anaphylaxis, with the 2020 Anaphylaxis Practice Parameter specifically recommending against their use for this purpose in adults 9

Evidence-Based Practice

• The American College of Allergy, Asthma, and Immunology notes that antihistamines and glucocorticoids together do not prevent biphasic reactions 9
• The Journal of Allergy and Clinical Immunology recommends that glucocorticoids should only be considered as adjunctive therapy after epinephrine and stabilization in patients with severe/prolonged anaphylaxis, history of idiopathic anaphylaxis, or underlying asthma, but their use is not supported by strong evidence 8

Anaphylaxis Treatment Guidelines

First-Line Treatment

• Epinephrine has vasoconstrictive, bronchodilatory, ionotropic, and mast cell stabilization properties that antihistamines and corticosteroids lack, making it the primary treatment for anaphylaxis 10

Adjunctive Therapy

• The American Academy of Allergy, Asthma, and Immunology is not mentioned in the cited references, however, antihistamines address only cutaneous manifestations (itching, urticaria, flushing) which are not life-threatening, with a slow onset of action—typically 30 minutes to start working and 60-120 minutes to reach peak plasma levels 10
• Patient preference for antihistamines over epinephrine should never be accommodated—epinephrine is non-negotiable as first-line therapy, as recommended by the Journal of Allergy and Clinical Immunology 11
• The evidence supporting antihistamines and glucocorticoids in anaphylaxis is of low certainty, with no high-quality randomized controlled trials demonstrating clear benefit in preventing biphasic reactions or improving mortality, according to the Journal of Allergy and Clinical Immunology 11
• The role of antihistamines in treating symptomatic cutaneous manifestations (urticaria, pruritus) is well-established and clinically accepted, as stated in the Journal of Allergy and Clinical Immunology 12
• The 2020 practice parameter from the Journal of Allergy and Clinical Immunology acknowledges that while these agents lack strong evidence, they remain part of standard practice for symptom control after epinephrine administration 11
• The Journal of Allergy and Clinical Immunology also states that glucocorticoids may be considered as adjunctive therapy after epinephrine and stabilization in patients with severe/prolonged anaphylaxis, history of idiopathic anaphylaxis, or underlying asthma, although evidence for benefit is limited 13

Use of H1 and H2 Antihistamines as Adjuncts in Anaphylaxis Management

First‑Line Therapy

• Intramuscular epinephrine (0.01 mg/kg, max 0.5 mg in the anterolateral thigh) must be administered immediately and must never be delayed or replaced by antihistamines, which only relieve cutaneous symptoms and do not treat life‑threatening airway or circulatory compromise. 14

Preferred H1 Antihistamine

• Diphenhydramine (first‑generation H1 blocker) is the preferred adjunct in anaphylaxis; give 1–2 mg/kg (maximum 50 mg) intravenously or orally. [15][16]
• Cetirizine (second‑generation H1 blocker) 10 mg orally can be used as a less‑sedating alternative when appropriate. 14

Dosing by Age Group

Adults

• Diphenhydramine 25–50 mg IV or oral. [14][15]
• Cetirizine 10 mg oral (alternative). 14

Children

• Diphenhydramine 1–2 mg/kg per dose (maximum 50 mg). [15][16]
• Preferred formulation: liquid oral (faster absorption) or IV if needed. [15][16]

Route of Administration

• Both intravenous and oral routes are acceptable for H1 antihistamines; liquid oral formulations are preferred over tablets for more rapid absorption. [15][16]
• In the hospital setting, IV administration allows tighter control in patients with hemodynamic instability. [15][16]

H2 Antihistamine Adjunct (Limited Evidence)

• Ranitidine may be added for additional H2 blockade: 1–2 mg/kg per dose (maximum 75–150 mg) orally or intravenously, administered twice daily for 2–3 days. [15][16]
• The use of H2 blockers in anaphylaxis is based on limited, low‑quality evidence and is not routinely recommended. [14][15]

Post‑Discharge Adjunct Therapy (2–3 Days)

• Diphenhydramine every 6 hours (or a non‑sedating second‑generation H1 blocker) for 2–3 days. [15][16]
• Ranitidine twice daily for 2–3 days if H2 blockade is desired. [15][16]
• Prednisone 1 mg/kg daily (maximum 60–80 mg) for 2–3 days. [15][16]

Clinical Considerations

• First‑generation H1 antihistamines (e.g., diphenhydramine) cause sedation and cognitive impairment, which can mask ongoing anaphylaxis symptoms; therefore, consider cetirizine when a less‑sedating option is appropriate. 14

Recommended Treatment Algorithm (Adjunctive Steps)